AstraZeneca Third Quarter and Nine Months Results 2010
Printer-friendly version
PDF version- Published date :
- 28 October 2010
Commenting on the results, David Brennan, Chief Executive Officer, said:
"We remain firmly on track to achieve our full year financial targets. The third quarter performance featured double-digit revenue growth in Emerging Markets.Revenue also increased in Western Europe and Established Rest of World. As expected, the impact of generic competition on several products and the absence of pandemic flu vaccine revenue led to a challenging quarter in the US.”
View more details:
http://info.astrazenecaevents.com
News Source : AstraZeneca Third Quarter and Nine Months Results 2010
Copy this html code to your website/blog and link to this press release.
More User Press Releases
- KOMBIGLYZE™ XR tablets approved in the US for the treatment of type 2 diabetes mellitus in adults
- US Appeal Court affirms preliminary injunction against Apotex in PULMICORT RESPULES patent litigation
- AstraZeneca announces co-promotion agreement with Daiichi Sankyo for NEXIUM in Japan
- AstraZeneca initiates phase IIB study for AZD9773 (CytoFab) as a treatment for severe sepsis
- European regulator backs nasal spray vaccine Fluenz for the prevention of seasonal influenza in children
- Positive agreement received for approval of VIMOVO in Europe
- New outcomes study for ticagrelor (BRILINTA™) to examine longer-term treatment for post- ACS patients
- AstraZeneca initiates phase III clinical development of fostamatinib for the treatment of rheumatoid arthritis
- Results of Zibotentan Phase III trial in castration resistant prostate cancer
- BRILIQUE (ticagrelor) receives positive opinion from European CHMP for the treatment of Acute Coronary Syndromes
Facebook
Twitter
del.icio.us
LinkedIn
Digg
StumbleUpon
Forward
Google
Favorite
Favorite on Technorati